Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19386611 | 0.76 | ALDH1A1 (0.44) | — | |
| SCHEMBL28974745 | 0.76 | ALDH1A1 (0.44) | — | |
| SCHEMBL3464668 | 0.75 | PSMD10 (0.47) | — | |
| SCHEMBL8779472 | 0.75 | PSMD10 (0.47) | — | |
| SCHEMBL28546483 | 0.75 | PSMD10 (0.47) | — | |
| SCHEMBL25176596 | 0.75 | PSMD10 (0.47) | — | |
| SCHEMBL8427107 | 0.75 | PSMD10 (0.47) | — | |
| SCHEMBL13446628 | 0.75 | PSMD10 (0.47) | — | |
| SCHEMBL8779442 | 0.75 | PSMD10 (0.47) | — | |
| SCHEMBL26639631 | 0.75 | PSMD10 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0807627-B1 | Anilide compounds as ACAT inhibitors | KOWA CO (JP) | 2005-12-28 | — | — | EP | disclosed |
| US-6825223-B2 | ACYL COENZYME A CHOLESTEROL ACYLTRANSFERASE (ACAT) INHIBITORS; 2-SUBSTITUTED BENZIMIDAZOLE, BENZOXAZOLE, AND BENZOTHIAZOLES | KOWA COMPANY, LTD. (JP) | 2004-11-30 | — | — | US | disclosed |
| US-20020037910-A1 | Novel anilide compounds and pharmaceutical compositions comprising them | SHIBUYA KIMIYUKI (JP) | 2002-03-28 | — | — | US | disclosed |
| US-6204278-B1 | Anilide compounds, including use thereof in ACAT inhibitition | KOWA COMPANY, LTD. (JP) | 2001-03-20 | — | — | US | disclosed |
| EP-0807627-A2 | Anilide compounds as ACAT inhibitors | Kowa Company Ltd. (JP) | 1997-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037910-A1 | Novel anilide compounds and pharmaceutical compositions comprising them | ACAT1, LCAT, SOAT1 | NLRP3 1037/4885SOAT1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.